Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: Thanks Chuck Moore :)

You quoted from an Aug 13, 2010 Press release as follows:

<As you may also know, we have been historically challenged in what we can publicly disclose on topics involving MMP and our relationship with TPL. This has largely been attributable to contractual restrictions contained within the agreements that govern the MMP joint-venture. Further, and at the request of TPL, we have also had restrictions placed on our ability to make public announcements by the Santa Clara Superior court. >

Continuing on in that press release and not quoted by you

<Needless to say we are inordinately frustrated by the contractual disclosure restrictions, and we know you are as well. So while we work towards the objective of having greater transparency on these issues that are of paramount importance to our shareholders, for now I must refer you to the disclosures we will make in our 10-K and the separate litigation update press release filed by us today, even though I know this will leave many of you with a desire to know more>

So either PTSC can disclose information under a separate litigation update press release or they have not only given TPL full authority to dictate what can and cannot be said about license agreements but also about our litigation with them. Should we be addressing all of our concerns about PTSC to Dan Leckrone rather than Cliff/Gloria and Carl?

Share
New Message
Please login to post a reply